The Johns Hopkins University-Uganda Clinical Trial Unit (JHU-CTU) renewal application aims to continue to support cutting edge HIV related research to expand scientific knowledge; and to identify innovative HIV prevention and treatment interventions that will help end the global HIV pandemic. The JHU-CTU has successfully participated as an NIH supported CTU, conducting HIV prevention and treatment clinical trials with two clinical research sites (CRSs) focused on PMTCT and high-risk women in Uganda over the past 25 years. This application builds on the highly successful JHU-CTU Network research on Prevention of Mother to Child Transmission (PMTCT) of HIV, Pediatric HIV treatment, and HIV Prevention among high risk HIV negative women. We propose to add two new Network affiliation (HIV Vaccines and Adult Therapeutics) and add three new CRSs to access diverse adult HIV-infected and most-at-risk adult populations in Kampala and Rakai Districts. These adult-focused CRSs cover some of the highest-HIV prevalence areas in Uganda with distinct urban, peri-urban, and rural settings, and will greatly enhance the JHU-Uganda CTU?s capacity to recruit diverse HIV-infected and at-risk populations for HIV treatment and prevention trials. The JHU-CTU plans to associate with the four DAIDS funded HIV Clinical Trial networks, which are addressing Adult HIV Therapeutics and Related Co-infections; Maternal Adolescent and Pediatric Therapeutics; HIV Prevention; and HIV Vaccines; and to contribute strongly to support their respective HIV Leadership Research Agendas. The proposed CRSs have access to distinct and diverse populations of HIV infected or at risk groups. These populations, including newly diagnosed HIV infected adults, as well as those on long term treatment, pregnant and breastfeeding HIV infected mothers and their HIV exposed infants; HIV infected adolescents (primarily long-term survivors from perinatal HIV infection); at risk adolescents/adults based on risky sex (e.g. sex workers, MSM); other at risk groups including fisher folk. Each of the Uganda CRSs have outstanding records of conducting HIV research.
Research Aims of the JHU-Uganda CTU application include: ? Assessing the safety and pharmacokinetics of new antiretroviral and immune interventions and novel models of delivery for both treatment and prevention ? Participating in multifaceted PrEP trials among high risk populations using new drugs/ delivery systems ? Evaluating the safety and immunogenicity of new HIV, TB, HBV vaccines, as well as vaccines for other co-infections seen among both HIV exposed and HIV infected populated populations ? Providing mentoring and training for rising investigators and clinical research staff in clinical trials The JHU-CTU/CRS investigators will continue their strong scientific contributions to the cutting-edge research agendas of the HIV leadership groups by actively contributing to the research agendas of the Network Leadership Scientific Committees and helping lead study protocols and other network related studies.
This application of the Johns Hopkins Uganda Clinical Trials Unit (CTU) aims to include five clinical research sites in the Kampala and Rakai Districts of Uganda to conduct NIH HIV prevention and HIV therapeutic trials; each of these CRSs have unique and diverse populations to participate in HIV and related co infection trials. Some of these unique groups, including recently infected adults, long term surviving HIV Infected adults, adults co infected with HBV or TB, perinatally infected adolescents and young adults, HIV Infected mothers and HIV infected children, as well as high risk HIV negative adult and adolescents. The JHU-Uganda CTU and its CRSs propose to participate in The HIV Prevention, The HIV Vaccine, The Maternal, Adolescent, Pediatric Therapeutics, and the Adult Therapeutics Clinical Trials Networks supported by National Institutes of Health.
|Ruiseñor-Escudero, Horacio; Familiar, Itziar; Nyakato, Mary et al. (2018) Building capacity in neurodevelopment assessment of children in sub-Saharan Africa: A quality assurance model to implement standardized neurodevelopment testing. Child Neuropsychol :1-16|
|Flynn, Patricia M; Taha, Taha E; Cababasay, Mae et al. (2018) Prevention of HIV-1 Transmission Through Breastfeeding: Efficacy and Safety of Maternal Antiretroviral Therapy Versus Infant Nevirapine Prophylaxis for Duration of Breastfeeding in HIV-1-Infected Women With High CD4 Cell Count (IMPAACT PROMISE): A Randomi J Acquir Immune Defic Syndr 77:383-392|
|Chernoff, Miriam C; Laughton, Barbara; Ratswana, Mmule et al. (2018) Validity of Neuropsychological Testing in Young African Children Affected by HIV. J Pediatr Infect Dis 13:185-201|
|Boivin, Michael J; Barlow-Mosha, Linda; Chernoff, Miriam C et al. (2018) Neuropsychological performance in African children with HIV enrolled in a multisite antiretroviral clinical trial. AIDS 32:189-204|
|Fowler, Mary G; Flynn, Patricia; Aizire, Jim (2018) What is new in perinatal HIV prevention? Curr Opin Pediatr 30:144-151|
|Balkus, Jennifer E; Palanee-Phillips, Thesla; Reddy, Krishnaveni et al. (2017) Brief Report: Dapivirine Vaginal Ring Use Does Not Diminish the Effectiveness of Hormonal Contraception. J Acquir Immune Defic Syndr 76:e47-e51|
|Currier, Judith S; Britto, Paula; Hoffman, Risa M et al. (2017) Randomized trial of stopping or continuing ART among postpartum women with pre-ART CD4 ? 400 cells/mm3. PLoS One 12:e0176009|
|Luecke, Ellen H; Cheng, Helen; Woeber, Kubashni et al. (2016) Stated product formulation preferences for HIV pre-exposure prophylaxis among women in the VOICE-D (MTN-003D) study. J Int AIDS Soc 19:20875|
|Mensch, Barbara S; Brown, Elizabeth R; Liu, Karen et al. (2016) Reporting of Adherence in the VOICE Trial: Did Disclosure of Product Nonuse Increase at the Termination Visit? AIDS Behav 20:2654-2661|
|Barlow-Mosha, Linda; Angelidou, Konstantia; Lindsey, Jane et al. (2016) Nevirapine- Versus Lopinavir/Ritonavir-Based Antiretroviral Therapy in HIV-Infected Infants and Young Children: Long-term Follow-up of the IMPAACT P1060 Randomized Trial. Clin Infect Dis 63:1113-1121|
Showing the most recent 10 out of 22 publications